Polyneuron raises CHF 22.5 million in a major Series A financing

Leading venture capital firm Sofinnova Partners led the Series A financing, together with New Enterprise Associates, which co-led the round

Basel, Switzerland, 28 March 2019 – Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced the closing of an oversubscribed CHF22.5 million Series A financing. The round was led by Sofinnova Partners and co-led by New Enterprise Associates (NEA), with the participation of existing investors. The proceeds will be used to perform a first-in-human trial with the company’s lead product, PN-1007, a potential treatment for anti-MAG neuropathy, a rare nervous system disease. The proceeds will also be used to broaden its Antibody-Catch™ product portfolio by advancing three programs through preclinical development. Using the Antibody-Catch™ technology, Polyneuron designs injectable, biodegradable glycopolymers that are able to target and eliminate the pathological

Press release